PROCEPT BioRobotics Corp Files 8-K
Ticker: PRCT · Form: 8-K · Filed: Aug 21, 2024 · CIK: 1588978
Sentiment: neutral
Topics: 8-K, disclosure
Related Tickers: PRCT
TL;DR
PRCT filed an 8-K, no major news.
AI Summary
On August 21, 2024, PROCEPT BioRobotics Corporation filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is not disclosing specific material events requiring immediate reporting under other standard 8-K items. The report was filed as of August 21, 2024.
Why It Matters
This filing indicates PROCEPT BioRobotics Corp is making a routine disclosure, but it does not contain information about significant new events that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K disclosure and does not contain information about significant new events or material changes.
Key Players & Entities
- PROCEPT BioRobotics Corporation (company) — Registrant
- August 21, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for PROCEPT BioRobotics Corporation?
The primary purpose of this 8-K filing is to report under the 'Other Events' item, indicating a routine disclosure rather than a specific material event.
What is the filing date of this 8-K report?
The filing date of this 8-K report is August 21, 2024.
Does this 8-K filing disclose any specific material events?
No, this 8-K filing is categorized under 'Other Events' and does not appear to disclose specific material events that would typically fall under other 8-K items.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is PROCEPT BIOROBOTICS CORPORATION.
What is the principal executive office address for PROCEPT BioRobotics Corporation?
The principal executive office address is 150 Baytech Drive, San Jose, California 95134.
Filing Stats: 954 words · 4 min read · ~3 pages · Grade level 16.7 · Accepted 2024-08-21 07:06:01
Key Financial Figures
- $0.00001 — ge on which registered Common Stock, $0.00001 par value per share PRCT The Nasdaq Glo
Filing Documents
- prct-20240821.htm (8-K) — 34KB
- 0001628280-24-037969.txt ( ) — 156KB
- prct-20240821.xsd (EX-101.SCH) — 2KB
- prct-20240821_lab.xml (EX-101.LAB) — 21KB
- prct-20240821_pre.xml (EX-101.PRE) — 12KB
- prct-20240821_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 21, 2024, PROCEPT BioRobotics Corporation (the "Company") announced that the U.S. Food and Drug Administration's (the "FDA") has granted 510(k) clearance of the Company's next-generation platform, the HYDROS Robotic System ( " HYDROS " ) . Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes HYDROS represents the next evolution in the delivery of Aquablation therapy, combining cutting-edge technology with user-friendly features designed to deliver better clinical outcomes for patients and healthcare providers. It utilizes a handpiece that comes pre-assembled with a single-use digital scope, eliminating the need for scope reprocessing. Key Features of the Fully Integrated HYDROS Robotic System Include: AI-Powered Treatment Planning: FirstAssist AI , built from a library of real-world Aquablation therapy procedures, uses advanced image recognition software to accurately identify critical anatomy on ultrasound and suggest an optimal treatment plan for each patient. Advanced Image Guidance: The system integrates next-generation ultrasound imaging, digital cystoscopy, and dual high-definition touchscreens providing enhanced visualization of the anatomy and simultaneous viewing of ultrasound and cystoscopy images. Robotic Resection: Utilizing a heat-free waterjet, the robot executes the surgeon-defined treatment plan to resect obstructive tissue while protecting critical anatomy. This enables efficient and predicable waterjet execution, standardizing the operative experience across a wide range of prostate sizes and shapes. Streamlined Workflow: Designed to improve the surgeon and staff experience at every stage of the Aquablation therapy procedur
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROCEPT BIOROBOTICS CORPORATION August 21, 2024 By: /s/ Alaleh Nouri Alaleh Nouri Chief Legal Officer and Secretary